دورية أكاديمية
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
| العنوان: | Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS |
|---|---|
| المؤلفون: | Martinez,Fernando J, Ferguson,Gary T, Bourne,Eric, Ballal,Shaila, Darken,Patrick, Aurivillius,Magnus, Dorinsky,Paul, Reisner,Colin |
| بيانات النشر: | Dove Press |
| سنة النشر: | 2021 |
| المجموعة: | Dove Medical Press |
| مصطلحات موضوعية: | International Journal of Chronic Obstructive Pulmonary Disease |
| الوصف: | Fernando J Martinez,1 Gary T Ferguson,2 Eric Bourne,3 Shaila Ballal,4 Patrick Darken,5 Magnus Aurivillius,6 Paul Dorinsky,3 Colin Reisner4 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA; 2Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 3AstraZeneca, Durham, NC, USA; 4AstraZeneca, Morristown, NJ, USA; 5AstraZeneca, Wilmington, DE, USA; 6AstraZeneca, Gothenburg, SwedenCorrespondence: Fernando J MartinezJoan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USATel +1 646 962 2748Email fjm2003@med.cornell.eduPurpose: In the Phase III, 24-week KRONOS study (NCT02497001), triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) reduced exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) MDI in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and no requirement for a history of exacerbations. We report a post hoc analysis investigating whether the benefits observed were driven by patients with ≥ 1 exacerbation in the 12 months prior to the study.Patients and Methods: Patients received BGF MDI 320/18/9.6 μg, GFF MDI 18/9.6 μg, budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, or budesonide/formoterol fumarate dry powder inhaler (BUD/FORM DPI) 400/12 μg twice-daily. Post hoc analyses were conducted on exacerbation and lung function results from patients with and without a documented exacerbation in the 12 months prior to the study.Results: Overall, 74% (1411/1896) of the modified-intent-to-treat (mITT) population had no moderate/severe exacerbations in the 12 months prior to the study. BGF MDI reduced exacerbation rates versus GFF MDI in the prior (58%; unadjusted p=0.0003) and no prior (48%; unadjusted p=0.0001) exacerbations subgroups. The magnitude of reduction in exacerbation rates was generally similar within subgroups for BGF MDI versus BFF MDI and BUD/FORM DPI. In the prior exacerbations subgroup, risk during ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/budesonideglycopyrrolateformoterol-fumarate-metered-dose-inhaler-impro-peer-reviewed-fulltext-article-COPDTest |
| الإتاحة: | https://doi.org/10.2147/COPD.S286087Test https://www.dovepress.com/budesonideglycopyrrolateformoterol-fumarate-metered-dose-inhaler-impro-peer-reviewed-fulltext-article-COPDTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EBE5409 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |